IN-VITRO AND IN-VIVO MUTAGENICITY STUDIES ON TAUROHYODEOXYCHOLIC ACID

被引:0
|
作者
TRIPODI, AS
FELETTI, F
MOLTENI, R
GERMOGLI, R
机构
[1] LISAPHARMA S P A, ERBA, ITALY
[2] D R DRUG RES S R L, DIV RES, MILAN, ITALY
[3] UNIV PAVIA, CHAIR TOXICOL 2, INST PHARMACOL 2, I-27100 PAVIA, ITALY
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 1993年 / 43-2卷 / 08期
关键词
BILIARY ACIDS; CAS; 2958-04-5; IO(R); PRAXIS(R); TAUROHYODEOXYCHOLIC ACID; MUTAGENICITY STUDIES;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The mutagenicity of a new biliary acid, taurohyodeoxycholic acid (THDCA, Io(R), Praxis(R), CAS 2958-04-5), was assayed by using 5 different tests. The Ames test (reverse mutation assay on Salmonella typhimurium) and the DNA damage and repair test (in Saccharomyces cerevisiae) allowed to study the genetic THDCA-induced mutations in prokaryotes and eukaryotes (doses of 100, 200 and 400 mug/plate or 100, 200 and 400 mug/ml, respectively). In vivo and in vitro chromosomal aberrations were studied by using micronucleus test in mice (doses of 100, 220 and 500 mg/kg in oral study and 50, 100 and 200 mg/kg in subcutaneous study) and human lymphocytes cytogenetic test (doses of 50, 100, 220 and 500 mug/ml of THDCA). At last the host-mediated assay was performed on THDCA-treated mice (following oral or subcutaneous administration) in order to test the potential mutagenic activity of its metabolites on a S. typhimurium strain. The results obtained in these studies showed that THDCA did not induce any signs of promutagenic, mutagenic or clastogenic direct or metabolite-mediated activity.
引用
收藏
页码:897 / 903
页数:7
相关论文
共 50 条